EXOME

all the information, none of the junk | biotech • healthcare • life sciences

FDA’s Andrew Mulberg Named to Amicus Therapeutics Regulatory Post

Xconomy New York — 

Amicus Therapeutics (NASDAQ: FOLD) has named Andrew Mulberg the company’s vice president of regulatory strategy. The pediatric gastroenterologist comes to Cranbury, NJ-based Amicus from the FDA, where he spent six years, most recently as the deputy director of the agency’s Division of Gastroenterology and Inborn Errors Products. Mulberg’s previous roles include posts at Johnson & Johnson (NYSE: JNJ).